explore -WSS

explore

author：leisure time 2025-09-27 12:35:25 - browse：89454

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Biden’s NIH nominee is languishing in Congress

Wikipedia

WSS

Create a giant ice tray with this foil pan hack to keep food cold this summer

Accuser who called Kevin Spacey 'vile sexual predator' admits he joked about incident

Bank of America ordered to pay more than $100 million for double charging fees, withholding rewards

The aspartame in Diet Coke probably isn’t giving you cancer

See Ryan Reynolds, Hugh Jackman suited up in 1st look at 'Deadpool 3': Photo

Rikers Island jail violence not addressed, NYC should be held in contempt: Fed monitor

Wikipedia

explore

focus

BioMarin wins approval for gene therapy to treat hemophilia A

Truvian presents data for its desktop blood

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Roche’s Alnylam deal shows drug firms interested in heart drugs

Heart attack and stroke risk calculators need revising

UHS says company favors patients whose insurance pays more

Medical records are filled with copy

Giraffe named Twiga, who was among the oldest cared for by humans, died at age 31 at East Texas zoo

ChatGPT in medicine: STAT answers readers' burning questions

What to watch for from Zogenix and Amicus clinical trials

focus

Truvian presents data for its desktop blood

UHS says company favors patients whose insurance pays more

Giraffe named Twiga, who was among the oldest cared for by humans, died at age 31 at East Texas zoo

The aspartame in Diet Coke probably isn’t giving you cancer

Giraffe named Twiga, who was among the oldest cared for by humans, died at age 31 at East Texas zoo

White House announces new plan to address the growing threat of xylazine in overdose crisis

leisure time

knowledge

Wikipedia

hotspot